



New Day in Medicine
Новый День в Медицине

NDM



TIBBIYOTDA YANGI KUN

Ilmiy referativ, marifiy-ma'naviy jurnal



AVICENNA-MED.UZ



ISSN 2181-712X.
EiSSN 2181-2187

4 (66) 2024

**Сопредседатели редакционной
коллегии:**

**Ш. Ж. ТЕШАЕВ,
А. Ш. РЕВИШВИЛИ**

Ред. коллегия:

М.И. АБДУЛЛАЕВ
А.А. АБДУМАЖИДОВ
Р.Б. АБДУЛЛАЕВ
Л.М. АБДУЛЛАЕВА
А.Ш. АБДУМАЖИДОВ
М.А. АБДУЛЛАЕВА
Х.А. АБДУМАЖИДОВ
Б.З. АБДУСАМАТОВ
М.М. АКБАРОВ
Х.А. АКИЛОВ
М.М. АЛИЕВ
С.Ж. АМИНОВ
Ш.Э. АМОНОВ
Ш.М. АХМЕДОВ
Ю.М. АХМЕДОВ
С.М. АХМЕДОВА
Т.А. АСКАРОВ
М.А. АРТИКОВА
Ж.Б. БЕКНАЗАРОВ (главный редактор)
Е.А. БЕРДИЕВ
Б.Т. БУЗРУКОВ
Р.К. ДАДАБАЕВА
М.Н. ДАМИНОВА
К.А. ДЕХКОНОВ
Э.С. ДЖУМАБАЕВ
А.А. ДЖАЛИЛОВ
Н.Н. ЗОЛотова
А.Ш. ИНОЯТОВ
С. ИНДАМИНОВ
А.И. ИСКАНДАРОВ
А.С. ИЛЬЯСОВ
Э.Э. КОБИЛОВ
А.М. МАННАНОВ
Д.М. МУСАЕВА
Т.С. МУСАЕВ
М.Р. МИРЗОЕВА
Ф.Г. НАЗИРОВ
Н.А. НУРАЛИЕВА
Ф.С. ОРИПОВ
Б.Т. РАХИМОВ
Х.А. РАСУЛОВ
Ш.И. РУЗИЕВ
С.А. РУЗИБОВЕВ
С.А.ГАФФОРОВ
С.Т. ШАТМАНОВ (Кыргызстан)
Ж.Б. САТТАРОВ
Б.Б. САФОВЕВ (отв. редактор)
И.А. САТИВАЛДИЕВА
Ш.Т. САЛИМОВ
Д.И. ТУКСАНОВА
М.М. ТАДЖИЕВ
А.Ж. ХАМРАЕВ
Д.А. ХАСАНОВА
А.М. ШАМСИЕВ
А.К. ШАДМАНОВ
Н.Ж. ЭРМАТОВ
Б.Б. ЕРГАШЕВ
Н.Ш. ЕРГАШЕВ
И.Р. ЮЛДАШЕВ
Д.Х. ЮЛДАШЕВА
А.С. ЮСУПОВ
Ш.Ш. ЯРИКУЛОВ
М.Ш. ХАКИМОВ
Д.О. ИВАНОВ (Россия)
К.А. ЕГЕЗАРЯН (Россия)
DONG JINCHENG (Китай)
КУЗАКОВ В.Е. (Россия)
Я. МЕЙЕРНИК (Словакия)
В.А. МИТИШ (Россия)
В.И. ПРИМАКОВ (Беларусь)
О.В. ПЕШИКОВ (Россия)
А.А. ПОТАПОВ (Россия)
А.А. ТЕПЛОВ (Россия)
Т.Ш. ШАРМАНОВ (Казахстан)
А.А. ЩЕГОЛОВ (Россия)
Prof. Dr. KURBANHAN MUSLUMOV (Azerbaijan)
Prof. Dr. DENIZ UYAK (Germany)

**ТИББИЁТДА ЯНГИ КУН
НОВЫЙ ДЕНЬ В МЕДИЦИНЕ
NEW DAY IN MEDICINE**

*Илмий-рефератив, маънавий-маърифий журнал
Научно-реферативный,
духовно-просветительский журнал*

УЧРЕДИТЕЛИ:

**БУХАРСКИЙ ГОСУДАРСТВЕННЫЙ
МЕДИЦИНСКИЙ ИНСТИТУТ
ООО «ТИББИЁТДА ЯНГИ КУН»**

Национальный медицинский
исследовательский центр хирургии имени
А.В. Вишневского является генеральным
научно-практическим
консультантом редакции

Журнал был включен в список журнальных
изданий, рецензируемых Высшей
Аттестационной Комиссией
Республики Узбекистан
(Протокол № 201/03 от 30.12.2013 г.)

РЕДАКЦИОННЫЙ СОВЕТ:

М.М. АБДУРАХМАНОВ (Бухара)
Г.Ж. ЖАРЫЛКАСЫНОВА (Бухара)
А.Ш. ИНОЯТОВ (Ташкент)
Г.А. ИХТИЁРОВА (Бухара)
Ш.И. КАРИМОВ (Ташкент)
У.К. КАЮМОВ (Тошкент)
Ш.И. НАВРУЗОВА (Бухара)
А.А. НОСИРОВ (Ташкент)
А.Р. ОБЛОКУЛОВ (Бухара)
Б.Т. ОДИЛОВА (Ташкент)
Ш.Т. УРАКОВ (Бухара)

4 (66)

2024

апрель

www.bsmi.uz

<https://newdaymedicine.com> E:

ndmuz@mail.ru

Тел: +99890 8061882

Received: 20.03.2024, Accepted: 10.04.2024, Published: 15.04.2024

УДК 612,8:616.28-76

THE EFFECTIVENESS OF BRONCHO-MUNAL IN THE CORRECTION OF CYTOKINE STATUS IN PATIENTS WITH CHRONIC SUPPURATIVE OTITIS MEDIA

Khamdamov B.Z. <https://orcid.org/0000-0003-1799-3777>

Nurov U.I. <https://orcid.org/0000-0001-7272-7418>

Uktamov I.G. <https://orcid.org/0000-0001-5247-3246>

Bukhara State Medical Institute named after Abu Ali ibn Sina, Uzbekistan, Bukhara, st. A. Navoi.

1 Tel: +998 (65) 223-00-50 e-mail: info@bsmi.uz

✓ Resume

The effectiveness of standard and combined treatment using broncho-munal therapy was evaluated based on the study of the levels of interleukin-2, interleukin-6 and tumor necrosis factor in 84 patients with chronic purulent otitis media. Broncho-munal 7mg was administered every day morning for 10 days. Such a 10-day cure was returned for 3 months and, as far as possible, an attempt was made to correct it to those days of the month when the drug was taken. It was found that by the end of the course of traditional therapy, a cytokine imbalance persists, indicating ongoing inflammatory changes. The inclusion of broncho-munal in the treatment regimen of patients with chronic suppurative otitis media significantly improved cytokine status.

Keywords: cellular and humoral immunity, broncho-munal, chronic suppurative otitis media

СУРУНКАЛИ ЙИРИНГЛИ ЎРТА ОТИТ БИЛАН ОҒРИГАН БЕМОРЛАРДА ЦИТОКИН ҲОЛАТИНИ ЯХШИЛАШДА ФОТОДИНАМИК ТЕРАПИЯНИНГ САМАРАДОРЛИГИ

Ҳамдамов Б.З., Нуров У.И., Ўктамов И.Г.

Абу али ибн Сино номидаги Бухоро давлат тиббиёт институти Ўзбекистон, Бухоро ш.,

А.Навоий кўчаси. 1 Тел: +998 (65) 223-00-50 e-mail: info@bsmi.uz

✓ Резюме

Фотодинамик терапия ёрдамида стандарт ва комбинацияланган даволаш самарадорлиги сурункали йирингли отит билан касалланган 2 беморда интерлейкин-6, интерлейкин-6 ва ўсма некрози омилларини ўрганиш асосида баҳоланди. Broncho-munal ҳар кун эрталаб 10 кун давомида қабул қилинди. Бу 10 кунлик даво 3 ой давомида такрорланди. Бу анъанавий даволаш курси охиригача, цитокинлар бир номутаносиблик давом этаётган яллигланиш ўзгаришлар кўрсатиб, давом деб топилди. Сурункали йирингли ўрта отит билан оғриган беморларни даволаш режимида бронхо-мунални киритиш цитокинлар ҳолатини сезиларли даражада яхшилади.

Калит сўзлар: хужайравий ва гуморал иммунитет, бронхо-мунал, сурункали йирингли ўрта отит.

ЭФФЕКТИВНОСТЬ ФОТОДИНАМИЧЕСКОЙ ТЕРАПИИ В КОРРЕКЦИИ ЦИТОКИНОВОГО СТАТУСА У ПАЦИЕНТОВ С ХРОНИЧЕСКИМ ГНОЙНЫМ СРЕДНИМ ОТИТОМ

Ҳамдамов Б.З., Нуров У.И., Уктамов И.Г.

Бухарский государственный медицинский институт имени Абу Али ибн Сины, Узбекистан,

г. Бухара, ул. А. Навои. 1 Тел: +998 (65) 223-00-50 e-mail: info@bsmi.uz



✓ Резюме

Эффективность стандартного и комбинированного лечения с использованием бронхо-мунал оценивалась на основании изучения уровней интерлейкина-2, интерлейкина-6 и фактора некроза опухоли у 84 пациентов с хроническим гнойным средним отитом. Бронхо-мунал по 7 мг вводили ежедневно утром в течение 10 дней. Такое 10-дневное лечение продолжалось в течение 3 месяцев, и, насколько это было возможно, была предпринята попытка скорректировать его до тех дней месяца, когда принимался препарат. Было обнаружено, что к концу курса традиционной терапии сохраняется дисбаланс цитокинов, свидетельствующий о продолжающихся воспалительных изменениях. Включение бронхо-мунала в схему лечения пациентов с хроническим гнойным средним отитом значительно улучшило цитокиновый статус.

Ключевые слова: клеточный и гуморальный иммунитет, бронхо-мунал, хронический гнойный средний отит

Introduction

Chronic suppurative otitis media accounts for a significant part in the structure of diseases of the ENT organs and can lead to serious intracranial complications [2, 10]. It is known that one of the reasons for the formation of chronic suppurative otitis media is a change in immunity [1, 4, 7], in which cytokines play a binding role between leukocytes different classes [5, 11]. This encourages the inclusion of other types of treatment in the treatment regimen [4, 9, 12]. The theoretical prerequisites for the use of immune therapy are the study of immune reactions in the context of the pathogenesis of diseases and laboratory evaluation of their effectiveness [3, 6].

Objective: to evaluate the effectiveness of standard and combined treatment with the use of broncho-munal in patients with chronic suppurative otitis media based on the study of levels of interleukin-2 (IL-2), interleukin-6 (IL-6) and tumor necrosis factor α (TNF).

Materials and methods

84 patients with chronic suppurative otitis media aged from 19 to 69 years were treated. All patients underwent physical examination, X-ray or computed tomography of the temporal bones, general clinical laboratory tests, audiometry. According to the indications, surgical interventions were performed. The cytokine content was studied in blood serum by solid-phase enzyme immunoassay using test systems and reagents from domestic manufacturers. Blood sampling was carried out in the day of admission, the first day after surgery and before discharge. The preparation of blood serum samples was carried out according to the generally accepted method [8].

All examined patients, depending on the activity of the inflammatory process, were divided into three groups. The first group consisted of 32 patients with mesotimpanitis (code H66.1 according to the International Classification of Diseases) who received only conservative therapy. The second group there were 28 people with epitympanitis (code H66.2), who simultaneously underwent sanitizing and functional operations on the middle ear. The third group included 24 people with epitympanitis, who, due to the vastness of pathological changes (a significant amount of destructive destruction, large cholesteatoma, labyrinth fistula, sub- and epidural abscesses, facial nerve paresis), underwent only a sanitizing operation. The comparison group included 15 practically healthy people: 8 men and 7 women, without respiratory pathology, aged 18 to 45 years.

The efficacy of broncho-munal was studied by analyzing the amount of cytokines in two groups (42 people each), in one of which broncho-munal was included in the standard therapy regimen and administered 1 tablet in the morning every day for 10 days (3 times).

The results of the study. Before the start of treatment, the titers of all tested cytokines depended on the severity of the inflammatory process. Thus, IL-2 indicators on the first day of hospitalization in patients of the first group were 1.6 ± 0.14 pg/ml, in the second group – 2.6 ± 0.38 pg/ml, in the third – 3.2 ± 0.34 pg/ml.

Fluctuations in the level of this cytokine in the entire sample ranged from 0.1 to 8.3 pg/ml and averaged 2.6 ± 0.21 pg/ml. Elevated IL-2 levels above average were found in 31 patients with epitympanitis, 9 (42.8%) of them were from the second group, 22 (56.4%) - from the third (Table 1).

A similar dependence on the severity of the inflammatory process on the first day of hospitalization was found in the study of IL-6 and TNF. In the first group, the IL-6 titers corresponded to 3.2 ± 0.09

pg/ml, TNF α – 3.9 ± 0.35 pg/ml. In patients with epitympanitis, cytokine levels increase significantly: in the second group, IL-6 levels increase to 7.9 ± 0.79 pg/ml ($p < 0.05$ compared to the first group), TNF α to 6.0 ± 0.79 pg/ml; in the third group to 8.0 ± 0.53 pg/ml ($p < 0.05$ compared to the first group) and 6.1 ± 0.53 pg/ml, respectively. IL-6 levels are higher than the average for the entire sample (6.8 ± 0.4 pg/ml), so the same was found only in patients of the second (14 people) and third groups (22 people). Above average (5.5 ± 0.36 pg/ml) TNF α values on the first day of treatment were found in 42 patients, 6 cases from the first group – 18.75%, 14 patients from the second group – 50.0% and 15 people from the third – 62.5% (Table 1).

Table 1

Distribution of cytokines in patients with chronic suppurative otitis media depending on the severity of the inflammatory process

Clinical group		IL-2 (pg/ml)	IL-6 (pg/ml)	TNF α (pg/ml)
Group 1 (n = 32)	Admission	$1,6 \pm 0,14$	$3,2 \pm 0,09$	$3,9 \pm 0,35$
	Extract	$2,3 \pm 0,17$	$3,9 \pm 0,17$	$2,0 \pm 0,20$
Group 2 (n = 28)	Admission	$2,6 \pm 0,38$	$7,9 \pm 0,79$	$6,0 \pm 0,79$
	Operation	$4,6 \pm 0,54$	$5,8 \pm 0,48$	$3,4 \pm 0,62$
	Extract	$3,4 \pm 0,40$	$5,8 \pm 0,48$	$3,4 \pm 0,62$
Group 3 (n = 24)	Admission	$3,2 \pm 0,34$	$8,0 \pm 0,53$	$6,1 \pm 0,53$
	Operation	$5,8 \pm 0,42$	$8,8 \pm 0,33$	$7,5 \pm 0,31$
	Extract	$4,3 \pm 0,29$	$6,9 \pm 0,37$	$5,1 \pm 0,42$
Control group (n = 15)		$1,44 \pm 0,06$	$1,1 \pm 0,48$	$0,61 \pm 0,2$

Surgical trauma increases the concentration of IL-2, little changing the levels of proinflammatory cytokines. After surgery, the concentration of IL-2 increases almost twice, reaching 4.6 ± 0.54 pg/ml in patients of the second group, 5.8 ± 0.42 pg/ml in patients of the third group ($p < 0.05$ to preoperative figures). The indicators of IL-6 and TNF α in the early postoperative period do not change significantly, continuing to depend on the degree of the destructive process, and are determined in patients of the third group as higher – 8.8 ± 0.33 pg/ml and 7.5 ± 0.31 pg/ml (Table 1).

By the end of the course of treatment and discharge from the hospital, an increase in the concentration of IL-2 and a decrease in the serum content of IL-6 and TNF α were found in all clinical groups in comparison with the figures at the time of admission. During these periods of the disease, the dependence of the concentration of cytokines on the degree of the destructive process remained, their minimum numbers were determined in patients of the first group, the maximum – in patients of the third group. So, in the first group, the levels of IL-2 by the time of discharge from the hospital were 2.3 ± 0.17 pg/ml, IL-6 – 3.9 ± 0.17 pg/ml, TNF α – 2.0 ± 0.2 pg/ml ($p < 0.05$ to the figures at admission). In patients of the second group, titers were determined to be higher 3.4 ± 0.4 pg/ml, 5.8 ± 0.48 pg/ml and 3.4 ± 0.62 pg/ml, respectively, increasing in the third group to 4.3 ± 0.29 pg/ml, 6.9 ± 0.37 pg/ml and 5.1 ± 0.42 pg/ml, significantly differing for all tested cytokines from the levels in the first group ($p < 0.05$). In addition, regardless of the timing of testing, the levels of all cytokines differed markedly from those of the control group (Table 1).

The clear dependence of cytokine levels on the degree of the inflammatory process, the effect of surgical trauma on their indicators and the preservation of cytokine imbalance by the time of discharge from the hospital predetermined the inclusion of broncho-munal in the treatment regimen of patients with chronic suppurative otitis media.

In patients who received only traditional therapy, there was no significant dynamics in cytokine levels by the time of discharge from the hospital. Thus, the titer of IL-2 in patients of this group at admission was 2.4 ± 0.26 pg/ml, at discharge – 2.8 ± 0.29 pg/ml, IL-6 – 6.6 ± 0.44 pg/ml at admission and 7.2 ± 0.46 pg/ml at discharge, TNF α – 5.3 ± 0.57 pg/ml and 5.9 ± 0.62 pg/ml. By the end of inpatient treatment (10-14 days of hospitalization), the levels of all tested cytokines significantly differed from those in the control group: IL-2 – $p < 0.05$, IL-6 – $p < 0.01$, TNF α – $p < 0.001$ (Table 2).

Nroncho-munal included in the treatment regimen for chronic suppurative otitis media, significantly changed the cytokine status of patients discharged from the hospital. By the end of conventional therapy, the majority of patients had higher levels of IL-2 compared to the levels at the beginning of therapy. By the time of discharge, the average IL-2 indicators had increased by more than 1.5 times and amounted to 4.0 ± 0.28 pg/ml ($p < 0.05$ compared to the indicators in the control group) (Table 2, Fig. 1). Cytokine activation enhances local resistance, accelerates remission of chronic inflammation and prevents relapses of the disease.

Table 2

Distribution of cytokines in patients with chronic purulent otitis media, depending on the inclusion of broncho-munal in the treatment regimen

Indicator		IL-2 (pg/ml)	IL-6 (pg/ml)	TNF α (pg/ml)
Standard therapy (n = 42)	Admission	$2,4 \pm 0,26$	$6,6 \pm 0,44$	$5,3 \pm 0,57$
	Extract	$2,8 \pm 0,29$	$7,2 \pm 0,46$	$9 \pm 0,62$
+Photodynamic therapy (n = 42)	Admission	$2,6 \pm 0,32$	$6,2 \pm 0,51$	$5,4 \pm 0,55$
	Extract	$4,0 \pm 0,28^*$	$3,8 \pm 0,22^*$	$1,3 \pm 0,2^*$
Control group (n = 15)		$1,44 \pm 0,06$	$1,1 \pm 0,48$	$0,61 \pm 0,2$

Note: * - significant differences in the concentration of interleukins at admission and before discharge ($p < 0.05$); bold indicates significant differences in the titers of interleukins in the formed groups before discharge ($p < 0.05$)

The concentration of IL-6 when using immune therapy significantly decreased by the end of the course of treatment and averaged 3.8 ± 0.22 pg/ml. This figure is 2 times less than the average values of the mediator at discharge in the group of patients treated according to the traditional scheme (7.2 ± 0.46 , $p < 0.05$), and in 1.5 times less than the figures for admission to the hospital (6.6 ± 0.51 pg/ml, $p < 0.05$) (Table 2, Fig.).

Nevertheless, the average IL-6 indicators significantly exceed those in the group of healthy donors (1.1 ± 0.48 pg/ml), which may indicate ongoing inflammatory changes, even when normalization of the objective status and otoscopic picture.

The dynamics of TNF α levels looks similar. In the group of patients with the use of immune therapy by the end of the course of treatment, there was a noticeable tendency to normalize the indicators - 1.3 ± 0.2 pg/ml, with levels in the control group - 0.61 ± 0.2 pg/ml. Significant differences with the levels of this cytokine were noted both at discharge in the group of patients receiving only traditional therapy - 5.9 ± 0.62 pg/ml ($p < 0.01$), and with the indicators at admission in the group of patients receiving combined immune therapy - 5.4 ± 0.55 pg/ml ($p < 0.05$) (Table. 2, fig.).

Conclusion

By the end of the course of traditional therapy of patients with chronic purulent otitis media, cytokine imbalance persists, indicating ongoing inflammatory changes. The inclusion of immune therapy in the treatment regimen of patients with chronic suppurative otitis media made it possible to significantly improve the cytokine status.

LIST OF REFERENCES:

1. Crawford DC, Akey DT, Nickerson DA. The patterns of natural variation in human genes. Annual Review of Genomics and Human Genetics. 2005;25(6):287-312. DOI: 10.1146/annurev.genom.6.080604.162309.
2. Seminsky IZH, Mayboroda AA. Features of cellular reactions in foci of inflammation of different etiology. Message 4. Factors, mechanisms and criteria of chronic inflammation. Journal of Infectious Pathology. 2000;7(3-4):33-8. [Seminskij IZh, Majboroda AA. Features cellular responses in areas of inflammation of different etiology. Message 4. Factors, mechanisms and criteria for chronic inflammation. Zhurnal Infekcionnoj Patologii. 2000;7(3-4):33-8. (In Russian)]

3. Vitkovsky UA, Kuznik BI, Solpov AV, Gvozdeva O.V., Rodnina OS. The state of immunity and lymphocytic-platelet adhesion in diffuse toxic goiter. *Medical immunology*. 2010;12(1-2):133-8. DOI: 10.15789/1563-0625-2010-1-2-133-138.
4. Vitkovskij YuA, Kuznik BI, Solpov AV, Gvozdeva OV, Rodnina OS Immunity and lymphocyte-platelet adhesion in diffuse toxic goiter. // *Medical Immunology*. 2010;12(1-2):133-8. (In Russian)]
5. Kuznik BI, Solpov A, Magen E. Lymphocyte-platelet crosstalk in grayes' disease. // *American Journal of the Medical Sciences*. 2014;347(3):206-10. DOI: 10.1097/maj.0b013e3182831726
6. Lyubin AV, Solpov AV, Shapovalov KG. platelet aggregation. *Far Eastern Medical Journal*. 2012(1):112. [Lyubin AV, Solpov AV, SHapovalov KG. Aggregation of thrombocytes. *Far East Medical Journal*. 2012;(1):112. (In Russian)]
7. Vitkovsky, Yu.A., Kuznik B.I., Solpov A.V. Results of a 10-year study of the mechanisms of lymphocytic-platelet adhesion. *Zabaikalsky Medical Bulletin*. 2008;(2):36-41. [Vitkovskij YuA, Kuznik BI, Solpov AV. Results of the 10-year study of mechanisms of lymphocyte-platelet adhesion. // *The Transbaikalian Medical Bulletin*. 2008;(2):36-41. (In Russian)]
8. Li N, Ji Q, Hjemdahl P. Platelet-lymphocyte conjugation differ between lymphocyte subpopulation. // *Thrombosis and Haemostasis*. 2006;(4):874-881. DOI: doi.org/10.1111/j.1538-7836.2006.01817.
9. Sigal A, Bleijs DA, Grabovsky V. The LFA-1 integrin supports rolling adhesion on ICAM-1 under physiological shear flow in a permissive cellular environment. *Immunology*. 2000;165(1):442-542. DOI: 10.4049/jimmunol.165.1.442.
10. Hawrylowich CM, Howells GL, Feldmann M. Platelet-derived interleukin-1 induces human endothelial adhesion molecule expression and cytokine production. // *Journal of Experimental Medicine*. 1991;174(4):785-90. DOI: 10.1084/jem.174.4.785.
11. Solpov A, Shenkman B, Vitkovsky Y, Brill G, Koltakov A, Farzam N, Varon D, Bank I, Savion N. Platelets enhance CD4+ lymphocyte adhesion to extracellular matrix under flow conditions: Role of platelet aggregation, integrins, and non-integrin receptors. // *Thrombosis and Haemostasis*. 2006;95(5):815-21. DOI: 10.1160/th05-07-0524.
12. Brandt E, Ludwig A, Peterson F, Flad HD. Platelet-derived CXC chemokines: old players in new games. // *Immunology Reviews*. 2000;(17):204-16. DOI:10.1034/j.1600-065x.2000.17705.
13. Dudek A, Nesselova I, Majo K. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8. *Blood*. 2003;101(12):4687-92. DOI: 10.1182/blood-2002-08-2363
14. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. // *Trends of Immunology*. 2004;25(9):489-95. DOI: 10.1016/j.it.2004.07.003
15. Solpov AV, Kuznik BI, Vitkovskij YuA, Yedelev D. Influence of interleukin 4 and 10 on haemostasis. // *Thrombosis and Haemostasis*. Abstr. XVII Congress of the ISTH, Washington D.C., August 14-21. 1999;(34):110. DOI:10.1016/s0248-8663(00)87076-9
16. Browder T, Folkman J, Pirie-Shepherd S. The haemostatic system as a regulator of angiogenesis. // *The Journal of Biological Chemistry*. 2000;275(3):1521-4. DOI:10.1074/jbc.275.3.1521

Entered 20.03.2024